SAR449028
Unknown / undisclosed
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
No clinical trials on ClinicalTrials.gov
No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.
No registered studies found. Not yet ingested, or none registered.
Competitive landscape
Other KIT drugs
barzolvolimab, bezuclastinib, Velzatinib, Briquilimab. Compare all 5 KIT drugs
4 other tracked programmes target this mechanism.
This drug's own stage for Chronic Spontaneous Urticaria: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| SAR449028: this drug | Stage not on record | Undisclosed | KIT | not yet graded | No reviewed efficacy summary in this indication | |
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Omalizumab (Xolair) | Approved | Monoclonal antibody | IgE (immunoglobulin E), IgE | Partial signal | NCT01287117: Change From Baseline to Week 12 in the Weekly Itch Severity Score (Baseline to Week 12): Placebo -3.63 Units on a scale (Standard Deviation 5.22) | Omalizumab 75 mg -6.46 Units on a scale (Standard Deviation 6.14) | Omalizumab 150 mg -6.66 Units on a scale (Standard Deviation 6.28) | Omalizumab 300 mg -9.4 Units on a scale (Standard Deviation 5.73) NCT01292473: Change in weekly itch severity score at week 12 vs placebo (-5.14): omalizumab 75 mg -5.87, difference -0.69 (95% CI -2.54 to 1.16), p=0.4637; 150 mg -8.14, difference -3.04 (95% CI -4.85 to -1.24), p=0.0011; 300 mg -9.77, difference -4.81 (95% CI -6.49 to -3.13), p<0.0001 (CT.gov posted results). | |
| Remibrutinib | Approved | Small molecule | Bruton's tyrosine kinase (BTK) | Reliable signal | No reviewed efficacy summary in this indication | |
| Barzolvolimab | Phase 3 | Monoclonal antibody | KIT | Partial signal | NCT06445023: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22). NCT06455202: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22). | |
| Bezuclastinib | Phase 3(overall) | Small molecule | KIT | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Velzatinib | Phase 3(overall) | Small molecule | KIT | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| AK139 | Phase 2 | Multispecific antibody | IL-4 receptor alpha / ST2 | not yet graded | No reviewed efficacy summary in this indication | |
| CM512 | Phase 2 | Multispecific antibody | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-3095 | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Briquilimab | Phase 1/2 | Monoclonal antibody | KIT | not yet graded | No reviewed efficacy summary in this indication | |
| Girocitinib | —(overall) | Small molecule | TYK2/JAK1 | Reliable signal | No reviewed efficacy summary in this indication | |
| SHR-3095 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
No upcoming readouts on record for this asset.